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els and sputum smear burden (P-value =0.54). There was an
association of TB severity score with lower levels of Vitamin D (P-
value =0.043). The general social functioning (SF)-12 health survey
scoring at enrolment in two arms did not differ signiﬁcantly (P-
value =0.786). However two months later ﬁndings indicate that
25-hydroxyvitamin D treatment had a positive effect on progress-
ing health-related quality of life (P-value =0.019) in each subscale
of physical health score (P-value =0.028) and mental health score
(P-value =0.025).
Conclusion: Our ﬁndings indicated that high dose cholecal-
ciferol supplementation can lead to improve clinical outcome in
tuberculouspatients especially inpatientswith calcidiol deﬁciency.
Tuberculosis alleviate quality of life and necessary at TB clinics to
apply strategies to improve the health-related quality of life of TB
patients. Therefore, we recommend vitamin D supplement therapy
for this purpose.
http://dx.doi.org/10.1016/j.ijid.2016.02.842
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Mycobacterium tuberculosis acetyltransferase
reduces the oxidative stress response through
expression of peroxisomal membrane
transporter protein
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Background: Mycobacterium tuberculosis (M.tb) survives inside
themacrophages bymanipulating thehost immune responses.Mtb
cell-wall associated glycoproteins play an important role in initia-
tion of host-pathogen interactions.
Methods & Materials: M.smegmatis mc2155 was used in this
study. Cloning and expression was performed in pSMT3 shuttle
vector. Invasion assay in HeLa cells. Survival assay, autopahgy,
oxidative stress response, immunostaining by ﬂuroscence micro-
scope and Western blot analysis was done in mouse macrophages.
Microbial adhesion to hydrocarbons (MATH) testwas performed to
assess bacterial hydrophocity. Bacterial susceptibility against cell
wall acting antibiotics was done with CFU (Colony Forming Unit)
assay.
Results: To identify novel Mtb glycoproteins, we employed a
multi-lectin system to capture glycoproteins from puriﬁed Mtb
cell wall and identiﬁed them by mass spectrometry analysis. A
novel protein as putative acetyltransferase (ACTase)was identiﬁed.
Recombinant M.smegmatis expressing the ACTase (MsmACTase)
showed increased invasion in human epithelial cells and survival
in mouse macrophages. Increased intracellular bacillary burden
was a result of inhibition of autophagy and ROS production due
to reduced expression of superoxide dismutase (SOD) and catalase
enzymes in Msm ACTase infected macrophages when compared
with wild-type and vector control (pSMT3) strains. Subsequent
studies showed that decreased ROS production was due to over
expression of ROS scavenging peroxisomal membrane protein 70
(PMP70) . MsmACTase showed increased expression of acylCoA
oxidase (ACOX-1), a classical marker enzyme for peroxiosmal
-fatty acid oxidation. MsmACTase also exhibited increased pro-
duction of nitric oxide and expression of inducible nitric oxide
synthase (iNOS) in infected macrophages. Moreover, MsmACTase
showed increased resistance to cell wall acting anti-TB drugs and
to lysozyme due to the increased cell surface hydrophobicity.
Conclusion: We have shown that acetyltransferase gene
(ACTase) of Mtb expressed in M.smegmatis aid intracellular
mycobacterial survival through inhibition of autophagy and oxida-
tive stress responses inmacrophages. The present study reports for
the ﬁrst time thatMsm ACTase scavengesH2O2 due to over expres-
sion of ROS scavengingperoxisomalmembraneprotein 70 (PMP70)
with which insights a new mechanism how the pathogen surpass
the host defense in Mtb infection. The above ﬁndings may lead to
identiﬁcation of a potential drug target for the antimycobacterial
therapy.
http://dx.doi.org/10.1016/j.ijid.2016.02.843
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Background: To describe the overall direct medical costs and
the compensation from health insurance systems and the TB con-
trol projects, andanalyze theeconomicburden for thewhole course
of treatment of pulmonary tuberculosis (PTB) patients in Shanghai.
Methods & Materials: The copy of invoices during the course
of TB diagnosis and treatment of 766 newly registered PTB patients
from 2013 were collected in four districts in Shanghai, meanwhile
these patients were investigated by questionnaire. Descriptive
analysis and ranksum test were employed.
Results: Themedians (inter-quartile range) of 766 PTB patients’
direct medical costs for whole course of treatment were 5757.4
(3749.87, 12632.98) yuan/person. All patients had an out-patient
cost with a median of 4605.3 (3490.8, 6335.2) yuan/person, con-
sisted of the cost of western medicine (47.6%), Chinese patent
drugs (19.9%), laboratory test fee (18.1%), inspection fee (12.1%)
and treatment/registered fee (2.3%). Among the western medicine
fee, hepatoprotectants accounted for 57.1%, followed by the ﬁrst-
line anti-TB drugs (20.2%) and second-line anti-TB drug (11.1%);
a higher proportion of hepatoprotectants in Chinese patent drugs,
reached 60.8%; in laboratory test fee, costs of liver function tests
(36.2%) and tuberculosis determination (31.5%) were relatively
higher; inspection fee was mostly CT cost, accounting for 82.9%.
The amount of cost was related to the District, age, the location
of household register, health insurance types, the level of medical
institutions, categoryof PTB. Themedianof theproportionof health
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insurance reimbursement from total cost was 8.8%, the proportion
of TB control project reimbursement from total costwas 33.8%, out-
of-pocket payment was account for 44.8% of total cost and 5.8% of
disposablehousehold income in2012. But therewas still about 6.5%
of PTB reached catastrophic health expenditure (>40%of disposable
income).
Conclusion: The direct medical costs of whole course of treat-
ment for PTB patients in Shanghai were relatively high, especially
the costs of hepatoprotectants, liver function laboratory test and
CT examination. Current TB control project reduced the economic
burden of PTB patients in a certain extent, but the item and pro-
portion of reimbursement, and the procedure of the cost reduction
still need to be optimized.
http://dx.doi.org/10.1016/j.ijid.2016.02.844
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Conﬁrmation of silent mutations in the rpoB
gene locus of M. tuberculosis isolates using
pyrosequencing and phenotypic DST
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Background: More than 95% cases of rifampicin resistance in
M.tuberculosis strains can be attributed to mutations in 81-bp
hotspot region of rpoB gene locus called Rifampicin Resistance
Determining Region. These mutations can be detected by rapid
molecular diagnostic techniques such as Line Probe Assay (LPA),
but detection of silent mutations on LPA may not necessarily con-
fer rifampicin resistance and result in false rifampicin resistance
reporting. These silent mutations can be conﬁrmed by phenotypic
Drug Sensitivity Testing (DST) and/or by DNA sequencing.
Following study was undertaken to conﬁrm silent mutations
using phenotypic DST (Gold standard) and pyrosequencing, a rapid
real timemethod for sequencing small DNA segments by synthesis.
Methods & Materials: Total 300 DNA extracts comprising of
101 silent mutation strains; 101 pan-sensitive, 96 MDR-TB and 02
rifampicinmono-resistant strainswereprocessed forpyrosequenc-
ing following detection by LPA.
Pyrosequencingwas performedwith sequence analysismode of
PyroMark Q96 ID system (Qiagen, Valencia, CA).
All 300 sputumconcentrateswerealsoprocessed forphenotypic
DST, using solid and liquid culture methods.
Results: Pyrosequencing detected mutations in all 101 silent
mutation strains, but 02 strains did not produce amino acid change
(true silent mutations) and were also rifampicin sensitive pheno-
typically. Maximum mutations were seen in 526 codon(35 strains)
followed by 511 codon region(30 strains). Two novel mutations
were reported: substitution in 529 codon CGA”CAA and 517-518
codon deletion.
However, only 51/99 true rifampicin resistant strains on Pyrose-
quencingwere rifampicin resistant byMGIT 960 and 57/99 by solid
DST. This proves that low level rifampicin resistance linked to spe-
ciﬁc rpoB mutations could be missed by phenotypic DST and this
could be attributed to the critical concentration of rifampicin used.
101pan-sensitive, 96MDR-TBand02rifampicinmono-resistant
strains used as controls were conﬁrmed by pyrosequencing and
showed 100% concordance with phenotypic DST.
Conclusion: Pyrosequencing is a conﬁrmatory tool for detection
of rifampicin resistance in silent mutation cases in M. tuberculosis
and reiterates the fact that liquid DST may miss some rifampicin
resistance compared to solid DST conferring mutations further
suggesting that the gold standard for rifampicin resistance be
reconsidered. Treatment outcome with these mutations is not well
known.
http://dx.doi.org/10.1016/j.ijid.2016.02.845
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Background: Against the backdrop evidenced in the threat
Tuberculosis poses to developing economies, especially its preva-
lence among people in their productive (15-45) years; this
preliminary study examined the phytochemical constituents and
antimycobacterial effect of four (4) aqueous and ethanolic extracts
from the fruit skin (epicarp) and leaf of Annona muricata Linn.
Methods & Materials: Extracts were prepared with distilled
water and 95% ethanol according to methods previously described.
Phytochemical analysis of the extracts were carried out follow-
ing standard protocols while the antimycobacterial activity was
assayed by employing the Drug susceptibility testing (DST) pro-
cedure in a Biosafety Level 3 facility. Lowenstein Jensen (LJ) media
were prepared with extracts at three concentrations (1, 40 and 250
g/ml) following the project design and subsequently inoculated
with 10-3 and 10-5 suspensions of both control (H37Rv) strain and a
clinical isolate (MTB-584) of Mycobacterium tuberculosis. LJ media
prepared with Rifampicin at 40 g/ml was used as the standard
drug for positive control while plain media with respective inocu-
lum served as negative control. Four Ziehl-Neelsen’s stain slides
were also prepared to conﬁrm the presence of organisms in the
two suspensions employed for the two strains tested. Plain media
inoculated with distilled water were employed as normal control
to check for possible contaminant. The inoculated media and con-
trol slants were placed in an incubator at 37oC and observed every
seven days for a period of 4 – 6 weeks.
